[go: up one dir, main page]

UY28201A1 - Compuestos de triazol útiles en terapia - Google Patents

Compuestos de triazol útiles en terapia

Info

Publication number
UY28201A1
UY28201A1 UY28201A UY28201A UY28201A1 UY 28201 A1 UY28201 A1 UY 28201A1 UY 28201 A UY28201 A UY 28201A UY 28201 A UY28201 A UY 28201A UY 28201 A1 UY28201 A1 UY 28201A1
Authority
UY
Uruguay
Prior art keywords
useful
therapy
compounds
triazol
triazol compounds
Prior art date
Application number
UY28201A
Other languages
English (en)
Inventor
Justin Stephen Bryans
Thomas Ryckmans
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of UY28201A1 publication Critical patent/UY28201A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

COMPUESTOS DE TRIAZOL ÚTILES EN TERAPIA Un compuesto de fórmula (1) O un derivado farmacéuticamente aceptable del mismo, en el que U, W, R, X, Y, Z, A, B, R, R,R, son como se definieron en la memoria descriptiva y en el capítulo reivindicatorio, siendo dichos compuestos útiles en el tratamiento de la dismenorrea.
UY28201A 2003-02-19 2004-02-19 Compuestos de triazol útiles en terapia UY28201A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0303852.8A GB0303852D0 (en) 2003-02-19 2003-02-19 Triazole compounds useful in therapy

Publications (1)

Publication Number Publication Date
UY28201A1 true UY28201A1 (es) 2004-09-30

Family

ID=9953327

Family Applications (1)

Application Number Title Priority Date Filing Date
UY28201A UY28201A1 (es) 2003-02-19 2004-02-19 Compuestos de triazol útiles en terapia

Country Status (11)

Country Link
CN (1) CN1751047A (es)
AR (1) AR043210A1 (es)
CL (1) CL2004000293A1 (es)
GB (1) GB0303852D0 (es)
GT (1) GT200400020A (es)
NL (1) NL1025527C2 (es)
PA (1) PA8596101A1 (es)
PE (1) PE20050222A1 (es)
TW (1) TW200500367A (es)
UY (1) UY28201A1 (es)
WO (1) WO2004074291A1 (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0325021D0 (en) * 2003-10-27 2003-12-03 Pfizer Ltd Therapeutic combinations
US7745630B2 (en) 2003-12-22 2010-06-29 Justin Stephen Bryans Triazolyl piperidine arginine vasopressin receptor modulators
DE102004001871A1 (de) * 2004-01-14 2005-09-01 Bayer Healthcare Ag Tricyclische Benzazepin-Derivate und ihre Verwendung
JP2008510789A (ja) * 2004-08-25 2008-04-10 ファイザー・インク トリアゾロベンゾジアゼピン及びバゾプレシンアンタゴニストとしてのそれらの使用
EP1877399A1 (en) * 2005-04-26 2008-01-16 Pfizer Limited Triazole derivatives as vasopressin antagonists
EP2356123B1 (en) 2008-11-13 2012-10-03 F.Hoffmann-La Roche Ag Spiro-5,6-dihydro-4h-2,3,5,10b-tetraaza-benzo[e]azulenes
WO2010057795A1 (en) * 2008-11-18 2010-05-27 F. Hoffmann-La Roche Ag Alkylcyclohexylethers of dihydrotetraazabenzoazulenes
BRPI0922303B1 (pt) 2008-11-28 2019-11-12 Hoffmann La Roche arilciclo-hexiléteres de di-hidrotetra-azabenzoazulenos, seu processo de preparação, composição farmacêutica que os compreende e uso
US8343961B2 (en) 2009-03-31 2013-01-01 Arqule, Inc. Substituted heterocyclic compounds
CN102812011A (zh) * 2009-11-16 2012-12-05 梅利科技公司 [1,5]-二氮杂环辛间四烯衍生物
US8420633B2 (en) 2010-03-31 2013-04-16 Hoffmann-La Roche Inc. Aryl-cyclohexyl-tetraazabenzo[e]azulenes
US8461151B2 (en) 2010-04-13 2013-06-11 Hoffmann-La Roche Inc. Aryl-/heteroaryl-cyclohexenyl-tetraazabenzo[e]azulenes
US8492376B2 (en) * 2010-04-21 2013-07-23 Hoffmann-La Roche Inc. Heteroaryl-cyclohexyl-tetraazabenzo[e]azulenes
US8481528B2 (en) * 2010-04-26 2013-07-09 Hoffmann-La Roche Inc. Heterobiaryl-cyclohexyl-tetraazabenzo[e]azulenes
US8513238B2 (en) 2010-05-10 2013-08-20 Hoffmann-La Roche Inc. Heteroaryl-cyclohexyl-tetraazabenzo[E]azulenes
US9006450B2 (en) * 2010-07-01 2015-04-14 Boehringer Ingelheim International Gmbh Compounds, pharmaceutical compositions and uses thereof
NZ608499A (en) 2010-10-07 2015-03-27 Takeda Pharmaceutical 1,4-oxazepane derivatives
RU2011122942A (ru) 2011-06-08 2012-12-20 Общество С Ограниченной Ответственностью "Асинэкс Медхим" Новые ингибиторы киназ
US8828989B2 (en) * 2011-09-26 2014-09-09 Hoffmann-La Roche Inc. Oxy-cyclohexyl-4H,6H-5-oxa-2,3,10b-triaza-benzo[E]azulenes as V1A antagonists
CA2847095A1 (en) * 2011-10-05 2013-04-11 F. Hoffmann-La Roche Ag Cyclohexyl-4h,6h-5-oxa-2,3,10b-triaza-benzo[e]azulenes as v1a antagonists
MY180688A (en) 2012-06-13 2020-12-07 Hoffmann La Roche New diazaspirocycloalkane and azaspirocycloalkane
CN102766674A (zh) * 2012-07-25 2012-11-07 辉源生物科技（上海）有限公司 食蟹猴抗利尿激素受体v1a拮抗剂筛选平台的建立
BR112015004111A2 (pt) 2012-09-25 2017-07-04 Hoffmann La Roche novos derivados bicíclicos
AR095079A1 (es) 2013-03-12 2015-09-16 Hoffmann La Roche Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo
EA201690179A1 (ru) * 2013-08-19 2016-06-30 Ф. Хоффманн-Ля Рош Аг Антагонисты рецептора v1a для лечения расстройств, связанных со сдвигом фазы сна
WO2015078803A1 (en) 2013-11-26 2015-06-04 F. Hoffmann-La Roche Ag NEW OCTAHYDRO-CYCLOBUTA [1,2-c;3,4-c']DIPYRROL-2-YL
SI3077396T1 (sl) 2013-12-05 2021-08-31 F. Hoffmann-La Roche Ag Sinteza trans-8-kloro-5-metil-1-(4-(piridin-2-iloksi)-cikloheksil)-5,6- dihidro-4H-2,3,5,10b-tetraaza-benzo(e)azulena in njegovih kristalnih oblik
AU2015238541B2 (en) 2014-03-26 2019-09-19 F. Hoffmann-La Roche Ag Condensed [1,4]diazepine compounds as autotaxin (ATX) and lysophosphatidic acid (LPA) production inhibitors
AU2015238537B2 (en) 2014-03-26 2019-08-01 F. Hoffmann-La Roche Ag Bicyclic compounds as autotaxin (ATX) and lysophosphatidic acid (LPA) production inhibitors
MA41898A (fr) 2015-04-10 2018-02-13 Hoffmann La Roche Dérivés de quinazolinone bicyclique
CA2992889A1 (en) 2015-09-04 2017-03-09 F. Hoffmann-La Roche Ag Phenoxymethyl derivatives
CR20180143A (es) 2015-09-24 2018-05-03 Hoffmann La Roche Nuevos compuestos biciclicos como inhibidores duales de atx/ca
BR112018006034A2 (pt) 2015-09-24 2018-10-09 Hoffmann La Roche compostos bicíclicos como inibidores de atx
CA2991612A1 (en) 2015-09-24 2017-03-30 F. Hoffmann-La Roche Ag New bicyclic compounds as dual atx/ca inhibitors
BR112018006024A2 (pt) 2015-09-24 2020-05-12 F. Hoffmann-La Roche Ag Compostos bicíclicos como inibidores de atx
CN110392679B (zh) 2017-03-16 2023-04-07 豪夫迈·罗氏有限公司 可用作双重atx/ca抑制剂的杂环化合物
JP7090099B2 (ja) 2017-03-16 2022-06-23 エフ．ホフマン－ラ ロシュ アーゲー Ａｔｘインヒビターとしての新規二環式化合物
EP3634963B8 (en) 2017-06-05 2023-03-29 Blackthorn Therapeutics, Inc. 1-(2-azaspiro[3.3]heptan-6-yl)-5,6-dihydro-4h-benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepine derivatives as v1a receptor antagonists for treating neuropsychological disorders
TW201938171A (zh) 2017-12-15 2019-10-01 匈牙利商羅特格登公司 作為血管升壓素Ｖ１ａ受體拮抗劑之三環化合物
HU231206B1 (hu) * 2017-12-15 2021-10-28 Richter Gedeon Nyrt. Triazolobenzazepinek
CN111170983B (zh) * 2019-12-26 2021-07-09 中国农业大学 一种苄硫基乙酰胺类化合物及其制备方法与应用
CN114644635B (zh) * 2020-12-21 2023-02-03 上海济煜医药科技有限公司 三氮唑类三并环衍生物及其制备方法和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8823475D0 (en) * 1988-10-06 1988-11-16 Merck Sharp & Dohme Chemical compounds
US5438035A (en) * 1994-06-24 1995-08-01 American Cyanamid Company Methods for controlling undesirable plant species with benzodiazepine compounds
US5753648A (en) * 1995-01-17 1998-05-19 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
HUP9904514A3 (en) * 1996-11-01 2000-10-30 Wyeth Corp 5h-pyrrolo[2,1-c][1,4]-benzodiazepin 3-carboxamide derivatives, process for their preparation, their use and pharmaceutical compositions containing them
ME00129B (me) * 1999-01-19 2010-10-10 Ortho Mcneil Janssen Pharmaceuticals Inc Triciklicnj benzodiazepini kao antagonisti receptora vazopresina
US7109193B2 (en) * 2001-04-12 2006-09-19 Wyeth Tricyclic diazepines tocolytic oxytocin receptor antagonists

Also Published As

Publication number Publication date
PE20050222A1 (es) 2005-04-13
WO2004074291A1 (en) 2004-09-02
NL1025527A1 (nl) 2004-08-23
GT200400020A (es) 2004-09-21
GB0303852D0 (en) 2003-03-26
CN1751047A (zh) 2006-03-22
PA8596101A1 (es) 2005-08-04
NL1025527C2 (nl) 2005-03-14
CL2004000293A1 (es) 2005-01-07
AR043210A1 (es) 2005-07-20
TW200500367A (en) 2005-01-01

Similar Documents

Publication Publication Date Title
UY28201A1 (es) Compuestos de triazol útiles en terapia
ECSP044992A (es) Inhibidores de la alquín-aril fosfodiesterasa-4
PA8556201A1 (es) Alquinos como inhibidores de metaloproteinasa de matriz
CY1106958T1 (el) Ν-αλκυλο-4-μεθυλεναμινο-3-υδροξυ-2-πυριδονες ως αντιμικροβιακα
GEP20053692B (en) Substituted Alkylamine Derivatives and Methods of Use
CR8481A (es) Derivados de triazol como antagonistas de la vasopresina
CY1109385T1 (el) Αναστολεις γυρασης και χρησεις αυτων
PA8509301A1 (es) Inhibidores no peptidicos de la union celular dependiente de vla-4 utiles en enfermedades inflamatorias, autoinmunes y respiratorias
CO5700767A2 (es) Procedimiento de tratamiento de rechazo de transplantes
MY135477A (en) 2-(2,6-dichlorophenyl)-diarylimidazoles
CY1109240T1 (el) Συνδυασμος που περιλαμβανει βαλσαρτανη, αμλοδιπινη και υδροχλωροθειαζιδιο
UY26380A1 (es) Inhibidores de fab i
NO20062256L (no) Hydroksyalkylsubstituerte pyrido-7-pyrimidin-7-oner
NO20055863L (no) W-karboksyarylsubstituerte difenylureaforbindelser som raf-kinaseinhibitorer
ECSP088484A (es) Derivados de quinazolina espirocíclicos como inhibidores de pde7
PE20030061A1 (es) 1-biaril-1,8-naftiridin-4-ona como inhibidores de fosfodiesterasa-4
ATE516031T1 (de) Verbindungen gegen krebs
NO20044548L (no) Fremgangsmate for fremstilling av 6-alkaliden-penemderivater
SE0003476D0 (sv) Compounds
DK1558580T3 (da) N-sulfonyl-4-methylenamino-3-hydroxy-2-pyridoner
PL372769A1 (en) Cyanoguanidine prodrugs
UY27451A1 (es) 2,5-diamidoindoles sustituidos y su utilización
UY28485A1 (es) Compuestos quimicos
CY1106385T1 (el) Χρηση παραγωγων της εποθειλονης για τη θepαπεια του υπepπαραθυρεοειδισμου
DOP2002000405A (es) 1-biaril-1,8-naftiridin-4-ona inhibidores de la fosfodisterasa-4.

Legal Events

Date Code Title Description
DESI Application deemed to be withdrawn

Effective date: 20140310